News

Three new calls for open access to JRC’s research infrastructures

Published on
| 3 years ago
Programmes
  • Joint Research Center

The Joint Research Center (JRC), the European Commission’s science and knowledge service, has launched three new calls for the purposes of training and capacity building in its scientific laboratories and facilities to people working in academia and research organisations, small and medium enterprises (SMEs), and more in general to the public and private sector. More information on this initiative can be found here.

The three new calls concern the following JRC facilities:

The Hopkinson Bar facility (HopLab) is used for the study of materials and of structural components to very fast dynamic loads, such as those due to blasts and impacts, where knowledge of the material behaviour under high strain-rates is necessary.

The ELSA Reaction Wall is a facility of unique dimensions and capabilities, capable of conducting experimental tests on full-scale specimens for the safety assessment of structures against earthquakes and other natural and man-made hazards.

The Nanobiotechnology Laboratory features state-of-the-art equipped facilities designed to foster interdisciplinary studies. Priorities are the detection of micro (nano)plastics and the characterisation of nano-biotechnology based health products.

To find more information about the call click on the title of the relevant facility.

 

 

 

Related news

myOverview

Sign up for personalised information

Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.

  • News in your domains
  • Event announcements
  • A personal dashboard
Sign up now

Only for stakeholders located in Flanders

Latest news

2055 articles available Browse all news
  • Health

One Health AMR Partnership: Call 2027 opening soon

The European Partnership on One Health Antimicrobial Resistance (OH AMR) is about to launch the joint transnational call 2027 (JTC2027) “Understand, Model and Stop AMR Transmission”. The call opens on 18 November 2026. The call will follow a two-step evaluation process.Novel and improved measures are urgently required...

Read more
  • Enhancing EU R&I

ERA in Practice: A guide for the research and innovation community

The European Commission Directorate-General for Research & Innovation has published ERA in Practice: A Guide for the R&I Community, developed with the support of INSPIRING ERA. The publication connects the four European Research Area policy priorities for joint action of the Pact for Research and Innovation (2021), with practical tools...

Read more
  • Culture and society

SSH Opportunities document for the 2027 Horizon Europe calls updated

Net4Society, the NCP network for Cluster 2, has published an updated edition of the document "Opportunities for Researchers from the Social Sciences and Humanities (SSH) in Horizon Europe". This document is designed to help potential applicants to find SSH-related call topics across the different parts of Horizon Europe in Work Programmes...

Read more
  • Agro-Food, Environment

Topic update - HORIZON-CL6-2027-02-FARM2FORK-05

On 5 November 2026, the European Commission published a correction for Horizon Europe topic HORIZON-CL6-2027-02-FARM2FORK-05. Under the section ‘Topic description - Scope’, the sentence on collaboration with projects funded under other topics in the work programme has been updated. The original text referred to...

Read more

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.